Valuations make buyers out of biotechs once seen as takeover targets

05/10/2013 | Reuters

Rising stock valuations due to promising drug data have transformed biotech drugmakers from acquisition targets into potential buyers, analysts said. Aside from rich valuations, easy access to financing and low interest rates provided alternatives to funding research and commercialization, a health banker said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC